血清阴性原发性抗磷脂综合征的产科结局与治疗:欧洲回顾性研究
该欧洲多中心回顾性研究纳入187例血清阴性APS女性并与285例血清阳性APS比较,发现血清阴性APS以产科表型为主、静脉血栓仅6%,不良产科事件累积发生率两组相似,但血清阳性组宫内死亡更高、子痫前期更多、活产孕周更短。血清阴性APS中治疗较未治疗显著改善不良产科事件累积发生率,阿司匹林与阿司匹林联合低分子肝素之间无差异。
要点
- 血清阴性APS以产科表型为主,静脉血栓仅6%。
- 两组不良产科事件累积发生率相似,血清阳性组宫内死亡更高。
- 血清阴性APS治疗较未治疗显著改善不良产科事件累积发生率。
核心结论
- 无常规抗磷脂抗体但有临床APS特征者可检出多种非标准抗磷脂抗体,支持血清阴性APS诊断并考虑类似血清阳性APS的治疗管理,但需设计良好的对照研究验证。
研究设计与样本
- 欧洲14个中心(奥地利、西班牙、意大利、斯洛文尼亚、法国)的回顾性研究,纳入187例血清阴性APS女性(平均33±5岁)并与285例血清阳性APS患者比较。
主要发现
- 血清阴性APS产科表型多于血栓表型,静脉血栓仅6%。
- 血清阴性APS与血清阳性APS不良产科事件累积发生率相似。
- 血清阳性APS宫内死亡率为15%对5%(p=0.03),子痫前期为7%对16%(p=0.048),活产孕周为36±3对38±3周(p=0.04)。
- 血清阴性APS中治疗较未治疗显著改善不良产科事件累积发生率(log rank<0.05)。
- 血清阴性APS中单用阿司匹林与阿司匹林联合低分子肝素之间无差异。
关键数值与推荐
- 纳入标准:血栓和/或产科APS(悉尼标准)、无常规抗磷脂抗体、至少一种持续存在的非标准抗磷脂抗体(IgA抗心磷脂抗体、IgA抗B2GPI、抗波形蛋白G/M、抗膜联蛋白V G/M、抗磷脂酰乙醇胺G/M、抗磷脂酰丝氨酸/凝血酶原G/M)。
- 排除标准:系统性红斑狼疮(SLE)或SLE样疾病、其他结缔组织病。
临床怎么用
- 对临床符合APS但常规抗磷脂抗体阴性的患者,可检测非标准抗磷脂抗体以支持血清阴性APS诊断。
- 血清阴性APS的治疗管理可参考血清阳性APS,但需对照研究进一步验证。
局限性
- 原文为回顾性研究,结论指出需设计良好的对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare characteristics, pregnancies and treatments during pregnancies of seronegative and seropositive antiphospholipid syndrome (APS), to analyse factors associated with obstetrical outcome. PATIENTS AND METHODS: Inclusion criteria were: (1) thrombotic and/or obstetrical APS (Sydney criteria); (2) absence of conventional antiphospholipid antibodies (APL); (3) at least one persistent non-conventional APL among IgA anticardiolipin antibodies, IgA anti-B2GPI, anti-vimentin G/M, anti-annexin V G/M, anti-phosphatidylethanolamine G/M and anti-phosphatidylserine/prothrombin G/M antibodies. The exclusion criteria were: (1) systemic lupus erythematosus ( SLE) or SLE-like disease; and (2) other connective tissue disease. RESULTS: A total of 187 women (mean 33±5 years) with seronegative APS were included from 14 centres in Austria, Spain, Italy, Slovenia and France and compared with 285 patients with seropositive APS. Seronegative APS has more obstetrical rather than thrombotic phenotypes, with only 6% of venous thrombosis in comparison to seropositive APS. Cumulative incidence of adverse obstetrical events was similar in seronegative and seropositive APS patients, although higher rates of intrauterine deaths (15% vs 5%; p=0.03), of preeclampsia (7% vs 16%, p=0.048) and lower live birth term (36±3 vs 38±3 weeks of gestation; p=0.04) were noted in seropositive APS. The cumulative incidence of adverse obstetrical events was significantly improved in treated versus untreated seronegative APS (log rank<0.05), whereas there was no difference between patients who received aspirin or aspirin-low-molecular weighted heparin combination. CONCLUSION: Several non-criteria APL can be detected in patients with clinical APS features without any conventional APL, with various rates. The detection of non-criteria APL and thus the diagnosis of seronegative APS could discuss the therapeutic management similar to seropositive APS, but well-designed controlled studies are necessary.
引用
- Abisror N, Nguyen Y, Marozio L, et al. Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study. RMD Open. 2020. PMID: 32848089. doi:10.1136/rmdopen-2020-001340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。